Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03379311 · ClinicalTrials.gov registry record · Phase 1
A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis
A Phase 1 study, sponsored by Allakos.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT03379311 is a Phase 1 study that has completed, run by Allakos. The registered enrollment target is 30 participants.
The verdict
NCT03379311, a Phase 1 study, has completed, sponsored by Allakos.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a Phase 1b, open-label, study to assess the effects of AK002, given as monthly intravenous infusion for 6 doses at up to 3 mg/kg.
Interventions
- DRUG AK002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-02-26 |
| Est. Completion | 2019-08-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03379311
The ClinicalTrials.gov registry entry for NCT03379311 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allakos, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AK002 is the first listed.
NCT03379311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03379311 about?
NCT03379311 is a clinical study titled "A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis". This is a Phase 1b, open-label, study to assess the effects of AK002, given as monthly intravenous infusion for 6 doses at up to 3 mg/kg.
What is the current status of trial NCT03379311?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2018-02-26. Estimated completion is 2019-08-08.
What interventions are being tested in trial NCT03379311?
The interventions under investigation include: AK002 (DRUG).
Who is sponsoring clinical trial NCT03379311?
This trial is sponsored by Allakos, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.